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ABSTRACT 
Benzene, a toxin and carcinogen found in air polluted by cigarette smoke, car exhaust, 
and industrial processes, is associated with the development of leukemia and 
lymphoma. Other than avoiding exposure, there is no current method to deter the 
effects of benzene. One potential strategy to prevent these effects is to engineer the 
bacteria of the human lung microbiome to degrade benzene. To evaluate this novel 
approach, we must verify that the bacteria remain viable within the lung 
microenvironment. To do so, lungs were harvested from rats and swabbed to determine 
the contents of the original lung microbiome. Then green fluorescent protein (GFP)-
transformed E. coli were introduced to the lungs and the lungs were ventilated for five 
minutes before being swabbed again. The lungs were sliced with a vibratome and 
cultured for three days. They were analyzed under a microscope and swabbed daily to 
determine how the bacteria disperse upon delivery and detect changes within the lung 
microbiome. If results show that introduction of a new bacterial species does not 
significantly change the lung microbiome over time, the project can move forward to test 
the engineered bacteria’s viability in the lung environment and effectiveness in rescuing 
lung cells from benzene’s toxicity.  
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